Medicine
Yuvezzi 1 mg/27.5 mg per mL eye drops
Yuvezzi 1 mg/27.5 mg per mL eye drops is a prescription medicine containing Brimonidine and Carbachol for ophthalmic use, marketed by Visus Therapeutics, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 36°F to 77°F (2°C to 25°C). Once a pouch is opened, store the…
Key facts
- Active ingredient (INN)
- Brimonidine and Carbachol
- Brand
- Yuvezzi
- Strength
- 1 mg/27.5 mg per mL
- Dosage form
- Eye drops
- Route
- Ophthalmic
- Packs
- 6 pouches
- Marketing authorisation holder
- Visus Therapeutics
- Manufacturer
- Visus Therapeutics
- Origin register
- US FDA, United States
- Storage
- Store at 36°F to 77°F (2°C to 25°C). Once a pouch is opened, store the single-dose vials in the foil pouch away from light until ready for use.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 18 February 2026
- Identifiers
- RxCUI 2736933, 2736939DailyMed set ID 68198098-0f33-458f-83b8-eb2a5ec69012NDC 84892-275Application NDA220142
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 6 pouch in 1 carton / 5 vial, single-dose in 1 pouch / .16 mL in 1 vial, single-dose | 84892-275-30 | Visus Therapeutics | 18 February 2026 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 28 January 2026 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Brimonidine and Carbachol is a fixed-dose combination of a cholinergic receptor agonist and an alpha-adrenergic agonist indicated for the treatment of presbyopia in adults. It is available as eye drops for ophthalmic use. MedsAcross supplies Brimonidine and Carbachol for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Brimonidine and CarbacholFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- YUVEZZI prescribing information (Visus Therapeutics) · U.S. National Library of Medicine, DailyMed
Need Yuvezzi 1 mg/27.5 mg per mL eye drops for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.